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Abstract
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder involving variations in the
transcriptome of many genes. AD does not affect all brain regions simultaneously. Identifying the differences
among the affected regions may shed more light onto the disease progression. We developed a novel method
involving the differential topology of gene coexpression networks to understand the association among affected
regions and disease severity.
Methods: We analysed microarray data of four regions - entorhinal cortex (EC), hippocampus (HIP), posterior
cingulate cortex (PCC) and middle temporal gyrus (MTG) from AD affected and normal subjects. A coexpression
network was built for each region and the topological overlap between them was examined. Genes with zero
topological overlap between two region-specific networks were used to characterise the differences between the
two regions.
Results and conclusion: Results indicate that MTG shows early AD pathology compared to the other regions. We
postulate that if the MTG gets affected later in the disease, post-mortem analyses of individuals with end-stage AD
will show signs of early AD in the MTG, while the EC, HIP and PCC will have severe pathology. Such knowledge is
useful for data collection in clinical studies where sample selection is a limiting factor as well as highlighting the
underlying biology of disease progression.
Background
The neuropathological hallmarks of Alzheimer’sd i s e a s e
(AD) are the accumulation of extracellular amyloid pla-
ques and intraneuronal neurofibrillary tangles (NFT) in
the brain. Certain brain regions have shown increased
susceptibilities to the pathological and metabolic charac-
t e r i s t i c so fA D[ 1 - 5 ] .H o w e v e r ,A Dd o e sn o ta f f e c ta l l
brain regions simultaneously. Comparing the gene
expression of the affected regions to identify the differ-
ences in the biological pathways perturbed in AD can
lead to greater insight into its pathogenesis and
progression.
Organising genes into co-expression networks helps in
comparing biological phenomena across brain regions,
and obtaining a global overview of the disease, which
can enable us to further understand the disease. As is
well known in Quantum mechanics, while the behaviour
of particles is not well understood or intuitive at the
quantum level, they do behave more intuitively at the
macro level. Hence, the application of systems biology
methods to understand complex diseases is crucial.
Gene coexpression networks can provide a view of the
relationship among genes, based on their gene expres-
sion profile, in a particular condition or time or disease.
Genes in a coexpression network are connected to one
another based on the similarity of their expression pro-
files. The rationale behind this is that coexpressed genes
may participate in the same pathway or form complexes
[6,7] that perform a specific function.
Numerous studies have analysed the similarities in
network structures and coexpression clusters [8-10].
Recently, a study by Luscombe et al. showed that impor-
tant biological knowledge can be gleaned from the dif-
ferences in the network topology of condition-specific
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knowledge, there have not been any analyses of the
topological differences of coexpression networks and
their interpretation in complex diseases. AD progresses
in stages and is described in terms of incipient (Braak
stages III-IV), mild/moderate (Braak stages IV-V) and
severe AD (Braak stages V-VI) [12]. However, AD does
not affect all brain regions simultaneously [13], and
regions that are affected later in the timeline of the dis-
ease progression will reveal evidence of early AD pathol-
ogy. With the recent deposition of laser captured
microdissected microarray data from discrete brain
regions affected in AD [1], we analysed the differential
network topology to identify associations among the
four different brain regions and the severity of AD.
In this study, our objective was to identify genes with
differential topology in gene coexpression networks corre-
sponding to different brain regions and observe the differ-
ence in AD severity across regions. We first identified the
differentially expressed (DE) genes between AD affected
and normal controls in the entorhinal cortex (EC), hippo-
campus (HIP), posterior cingulate cortex (PCC) and mid-
dle temporal gyrus (MTG). Then coexpression networks
for the regions were built using the common DE genes
between regions. Next, we investigated the topological dif-
ferences between coexpression networks, and identified
the significant biological pathways of the sets of genes
with no topological overlap across the region-specific net-
works. The significant pathways along with network gene
connectivity were used to determine the association
between disease stage and brain region, and the relation-
ship between gene activity and disease severity. Figure 1
shows the sequence of analyses undertaken in this study.
Results suggest that the MTG is not as severely affected as
the other three regions in this dataset. We provide further
confidence in our analyses and results by comparing
results from the MTG with those from the posterior visual
cortex and superior frontal gyrus. Through illustration
with AD relevant genes, we show that the change in con-
nectivity of a gene can shed light on its behaviour in the
disease stage. Furthermore, since we used laser captured
microdissected expression data, we could compare differ-
ent brain regions without any issues regarding regional
variability due to cell type distribution. Such an analysis
has implications for AD data collection, early AD detec-
tion and the identification of markers of early pathology.
Methods
Data
For our analyses we used recent microarray (Affymetrix
Human Genome U133 Plus 2.0) expression data
obtained via laser captured microdissection and contain
data from different brain regions that are either histo-
pathologically or metabolically relevant to Alzheimer’s
disease (AD) [1]. We used the data collected (mean
postmortem interval of 2.5 hours) from the entorhinal
cortex [EC; Brodmann area (BA) 28 and 34], hippocam-
pus [HIP; CA1 region], middle temporal gyrus [MTG;
BA 21 and 37], and posterior cingulate cortex [PCC; BA
23 and 31]. Alzheimer’s affected subjects had a Braak
stage ranging from III to VI [12] with a Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD)
neuritic plaque density of moderate or frequent [14].
For each sample, expression data was obtained from
approximately 500 pyramidal neurons. The data con-
sisted of 13 control subjects and 10 AD individuals for
EC, 13 control subjects and 10 AD individuals for HIP,
12 control subjects and 16 AD individuals for MTG,
and 13 control subjects and 9 AD individuals for PCC.
Probe sets were processed for differential expression
(DE) by using the two-class significance analysis of
microarrays (SAM) [15], based on GC Robust Multi-
array Average (GC-RMA) summarised expression values
[16]. SAM uses a modified t-statistics method to identify
DE genes. Within each brain region, AD affected sub-
jects and unaffected age-matched controls were com-
pared to identify DE genes. After obtaining four sets of
DE genes, one per brain region, we identified the com-
mon (intersection) DE genes between two regions of
interest. The common genes were used to create two
gene coexpression networks for the pair of regions from
which the common genes were selected. These sets of
common genes between regions will be referred to as
the ‘intersection genes’ in the manuscript for clarity.
Significant biological pathways were identified using
the well annotated GeneGo MetaCore™ database [17].
MetaCore™ is based on a proprietary manually curated
database of human protein-protein, protein-DNA and
protein compound interactions, metabolic and signalling
pathways and the effects of bioactive molecules in gene
expression [17].
Construction of co-expression networks
We used the co-expression network (CoExp) method
developed by Ruan and Zhang [18,19] to construct gene
co-expression network by measuring the pairwise
expression similarity between genes. Nodes in the net-
work correspond to genes and edges represent expres-
sion similarities between genes. In this study, we used
the Pearson correlation coefficient (PCC) for the similar-
ity measure. For two genes to be considered as co-
expressed, their expression profiles needed to satisfy at
least one of the following conditions: (1) their correla-
tion coefficient is higher than 0.3, and one gene is
ranked as the top-3 most correlated gene of the other;
(2) the correlation coefficient between them is higher
than a user defined Pearson correlation coefficient
threshold t (t = 0.7 or 0.8 in all the networks generated
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Page 2 of 11Figure 1 Schematic of analyses carried out in this study. This illustrates the flowchart of analysis performed in this study. R1 and R2 refer to
region 1 and region 2, respectively. Differentially expressed (DE) genes were identified by comparing AD affected to normal controls within each
region. When pairs of regions were compared, the coexpression network was built using the common (intersection) DE genes between the
regions. Genes with no topological overlap between the coexpression networks were taken for further analyses.
Ray and Zhang BMC Systems Biology 2010, 4:136
http://www.biomedcentral.com/1752-0509/4/136
Page 3 of 11here) and one gene is within the top-50 most correlated
gene of the other. According to the first condition, if 3
genes are correlated to gene A with correlation coeffi-
cients equal to 0.3, 0.32, and 0.4 then they get linked to
gene A. On the other hand, if the 3 genes are correlated
to gene A with correlation coefficients equal to 0.3, 0.28
and 0.29, then only 1 gene would get linked to gene A.
However, this scenario rarely, if at all, occurs in gene
expression data with a correlation coefficient threshold
of 0.3 (see Additional file 1), hence the minimum con-
nectivity in the networks in this paper is 3.
This approach was taken to create a sparse coexpres-
sion network. Minimally complex, sparse gene networks
have been shown to be more robust to perturbations
and may be a constraint in shaping the evolution of
gene network complexity [20]. The CoExp method has
been previously successfully applied to study Alzhei-
mer’s disease [21].
Topological overlap between coexpression networks
A coexpression network was constructed for two brain
regions under study separately using the differentially
expressed genes that were common to both regions, i.e.
the intersection genes (see Methods). Additionally, gene
coexpression networks were also created using the DE
genes obtained by comparing AD affected and normal
controls in order to compare affected and controls
within each region. The coexpression network obtained
from CoExp is a binary adjacency matrix with 0 refer-
ring to no link between two genes and 1 corresponding
to a link between the genes.
Let the two coexpression networks be referred to as
network1 and network2 corresponding to brain region 1
and brain region 2, respectively. Since network1 and net-
work2 were built using the intersection genes between
regions 1 and 2, the nodes in both the networks are the
same, although the connections among them are differ-
ent. Let each node/gene in the network be denoted as
genei where i = 1, 2,...,m and m is the total number of
nodes in the network.
Topological overlap between gene coexpression net-
works, network1 and network2, refers to the overlap of
the genes connected to genei in network1 and network2,
i.e. overlap of the neighbourhoods of genei.L e tt h e
genes connected to a genei in network1 be referred to as
X and those in network2 be referred to as Y.T h ec o n -
nectivity or degree of genei in network1 is d1i and that
in network2 is d2i. The topological overlap (TO) for
genei between network1 and network2 is given by
TO
XY
dd
gen
ii
i e =

max(, ) 12
(1)
The larger degree of genei was considered instead of
the smaller degree in order to reduce false negatives.
Consider the following example. Let the neighbourhoods
of genei be X =2 0 0i nnetwork1 and Y =1 0i nnetwork2
with X ∩ Y = 10, then with max(d1i, d2i) = 200, TO =
0.05. On the other hand, with min(d1i, d2i)=1 0 ,T O=
1. Since our aim was to identify genes with a topological
difference (i.e. low TO) between coexpression networks,
this gene would have been discarded (false negative) if
the smaller degree was used as it would result in a high
TO value. The actual amount of similarity between
these two neighbourhoods is only 5% (i.e. 10/200 unique
genes). The TO values in this analyses were rounded
upto 4 decimal places.
If the topology of coexpression networks are representa-
tive of the ‘biological activity’ o fag e n eu n d e rac e r t a i n
condition or in a specific region, then genes with high
topological overlap between two region-specific networks,
may not differ greatly in their activity in the two brain
regions. However, genes with low topological overlap
probably have roles/activities that are region-specific or
condition-specific. As a specific case for this analysis,
genes with the maximum topological difference, i.e. TO =
0 (zero topological overlap since there are no overlapping
genes between their neighbourhoods) between the two
networks were selected for further analyses in this study.
Genes with other values of topological overlap, if properly
justified, can also be considered. Comparisons against
1000 random networks (random additions or deletion of
links to the original network while keeping the degree of
the genes equal to the original network) using t-statistics
were made to assess the significance of the zero TO genes.
The actual gene co-expression networks had a lower num-
ber of zero TO genes compared to the random networks.
The significance values (p values) were calculated (with
999 degrees of freedom) using the following formula,
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where μ1 is the mean number of zero TO genes in the
real network; μ2 is the mean number of zero TO genes
in randomised networks; SD is the standard deviation of
the number of zero TO genes in the 1000 random net-
works; n1 is the number of random nets (i.e. 1000) and
n2 is the number of real networks (i.e. 1).
Some studies have used the topological overlap mea-
sure for identifying metabolites that are in the same
functional class [22], or for module detection, i.e. clus-
tering of genes [23]. Other network measures, not
necessarily topological overlap, have been used for other
Ray and Zhang BMC Systems Biology 2010, 4:136
http://www.biomedcentral.com/1752-0509/4/136
Page 4 of 11objectives as in [8-11]. Although the topological overlap
measure introduced in this article is similar to the ideas
proposed in [22], it is still very different. The main dif-
ference lies in the determination of the topological over-
l a pa si tw a sm o t i v a t e db yv e r yd i f f e r e n tb i o l o g i c a l
objectives. While other topological measures were devel-
oped for the purposes of examining relationships among
genes within the same network, our topological measure
was developed to compare two different networks and
use it to study the behaviour of a particular gene in
separate gene coexpression networks that correspond to
different brain regions. In this manner, the measure was
used as a means of computing gene coexpression net-
work differences and then associating these differences
with AD severity. Such a use of a topological overlap
measure has never been employed before.
Results and Conclusions
Genes with zero topological overlap between brain
regions
Significance analysis of microarrays (SAM) [15] was
used to identify differentially expressed (DE) genes
between AD affected and unaffected controls within
each of the four brain regions -en-torhinal cortex (EC),
hippocampus (HIP), posterior cingulate cortex (PCC)
and middle temporal gyrus (MTG) (Table 1). The analy-
sis steps are shown in Figure 1. DE genes have been
considered to be disease associated [24-27]. Other stu-
dies have used DE genes for class prediction [28-32].
Six sets of intersection genes (see Methods) were
obtained from six comparisons - (1) EC and HIP; (2) EC
and PCC; (3) EC and MTG; (4) HIP and PCC; (5) HIP
and MTG; (6) PCC and MTG (Table 2). Coexpression
networks were built for each region using the intersec-
tion genes (see Additional file 2). For instance, the gene
expression of the 2041 intersection genes between the
EC and HIP were taken from the EC and used to build
the coexpression network of the EC (ECnet), while the
expression of the 2041 genes in the HIP were used to
build the network corresponding to the hippocampus
(HIPnet). Therefore, there were three different coexpres-
sion networks for each of the four regions resulting in
twelve coexpression networks.
The aim of this study was to identify the genes with
differential topology between the region-specific coex-
pression networks. The biological processes represented
by these genes would provide an idea of the difference,
if any, in disease severity among the different regions.
Therefore, after the coexpression networks were built
for each region, the topological overlap (TO) between
the region-specific networks was calculated for each pair
of regions analysed. The numbers of genes with zero
TO between the coexpression networks are shown in
Table 2. These observed number of TO genes differ sig-
nificantly from random expectation (p < 0.0001, see
Methods). The entire list of these TO genes are pro-
vided as Additional file 3.
Although a few are mentioned here, there were many
AD relevant genes in all the sets of zero TO genes (see
Additional file 3). BR serine/threonine kinase 2 (SAD1),
calcitonin gene-related peptide-receptor component pro-
tein (RCP9), calcitonin 1 (CALCA), cyclin-dependent
kinase 2 (CDK2), coronin actin binding protein 1B
(CORO1B), interleukin 10 (IL10), ninjurin 1 (NINJ1),
oxidative-stress responsive 1 (OXSR1 ), phospholipase c
eta2 (PLCH2), spectrin beta non-erythrocytic 1
(SPTBN1), plexin B2 (PLXNB2 ), synapsin III (SYN3),
syntaxin 16 (STX16), lim domain and actin binding 1
(LIMA1), toll-like receptor 4 (TLR4), yy2 transcription
factor (YY2), microtubule associated serine/threonine
kinase 1 (MAST1), were some of the AD associated
g e n e si nt h el i s to f3 0 0z e r oT Og e n e sb e t w e e nt h e
ECnet and HIPnet, that were associated with processes
such as protein transport, cytoskeletal organisation, neu-
rotransmitter release etc. [33-37]. YY2 is highly similar
to the evolutionarily well-conserved zinc finger gene
YY1 [38], which activates beta-site amyloid precursor
protein-cleaving enzyme 1 (BACE1) expression [39].
BACE1, which was present in the list of 271 genes
between HIPnet and MTGnet, is necessary for the gen-
eration of beta-amyloid peptides, the principal constitu-
ents of senile plaques, in AD subjects [40,41]. Toll-like
receptor 4 (TLR4) signalling pathway has been
Table 1 Number of differentially expressed (DE) genes
and associated false discovery rate (FDR) in the four
brain regions
Region Number of DE genes (FDR)
Entorhinal cortex (EC) 5776 (0.5%)
Hippocampus (HIP) 5264 (0.5%)
Middle temporal gyrus (MTG) 3379 (0.5%)
Posterior cingulate cortex (PCC) 6536 (0.4%)
Table 2 Number of intersection genes, i.e. genes
common to the set of DE genes of the regions being
compared, and the number of genes with zero
topological overlap
Regions
compared
No. intersection
genes
No. zero TO genes between
regions
EC-HIP 2041 300
EC-MTG 1398 192
EC-PCC 2424 324
HIP-MTG 1248 271
HIP-PCC 3118 267
PCC-MTG 1582 180
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the brain of Alzheimer’s disease subjects [42,43]. All
three members of the caveolin gene family - caveolin-1,
-2, and -3, were present in the set of zero TO genes,
specifically in the list of 271 genes between MTGnet
and HIPnet, 300 genes between the ECnet and HIPnet,
and 324 genes between ECnet and PCCnet. This gene
family has been implicated in AD, diabetes and cancer
[44].
Association between brain regions and disease severity
Table 3 lists the top few significant pathways, identified
by GeneGo [17], in the six sets of zero TO genes. It was
observed that the pathways represented by the zero TO
genes could be broadly divided into two categories -
inflammation/immune related pathways, and transport/
cytoskeleton remodelling pathways.
The EC has been shown to be the germinal site of AD
followed by other brain regions [12,45]. Impairment of
the transport (“Neuronal traffic jams”) and cytoskeletal
related processes in early AD pathogenesis has been
shown by several studies [46-48]. Since the EC and HIP
get affected earlier in the disease, subjects affected with
severe AD, would have greater disruptions in the cytos-
keletal, transport, energy metabolism, and lipid metabo-
lism systems in these regions, resulting in secondary
biological processes becoming highly active in the later
stages of AD progression. Inflammation is a secondary
process, i.e. a defensive reaction, that follows the pertur-
bation of some other biological processes. Inflammation
and cell death seem to be the final biological symptoms
of AD. This is probably why the inflammation and
immune response pathways were over-represented in
the list of zero TO genes of regions that are afflicted
with late AD pathology and overshadowed the biological
pathways that triggered them.
On the other hand, transport and cytoskeleton path-
ways were highly significant, compared to other path-
ways, in the sets of 192, 271 and 180 genes obtained
when MTG was being compared to the other regions.
This implied that the inflammatory and immune
responses were not yet dominant in the MTG. Further-
more, pathways that counteract cell death were probably
active in MTG, since one of the significant pathways
was the role of inhibitor of apoptosis proteins (Table 3),
which suppresses apoptotic cell death. Since inflamma-
tion dominates other pathways in the later stages of AD
[49,50], but such pathways were not highly significant in
these sets of zero TO genes, as well as the fact that pro-
tective pathways were still highly significant, it can be
postulated that the degenerative effects of AD in the
MTG was less severe than that in the EC, HIP and
PCC. From these results, we concluded that EC, PCC
and HIP show pathogenesis of late stage AD while the
MTG shows early AD pathology.
We hypothesised that the reason that transport and
cytoskeletal related zero TO genes were showing up in
MTG comparisons was probably because the source
pool of genes, i.e. the set of intersection DE genes
between the MTG and any other region contained
mainly transport and cytoskeletal related genes. This
m e a n tt h a tt h eM T Gh a dm o r eD Eg e n e si n v o l v e di n
transport and cytoskeleton compared to genes that were
involved in inflammation and immune response. We
reasoned that this situation could be because the MTG
showed very early signs of AD.
The laser captured microarray dataset generated by
Liang et al. included the microarray data of 6 regions -
Table 3 Significant biological pathways in the set of zero TO genes between regions
Region comparison Pathways p value (FDR = 0.05)
EC-HIP Bacterial infections in CF airways 1.27e-4
Transcription NF-kB signalling pathways 1.46e-4
Immune response MIF in innate immunity response 2.34e-4
G-protein signalling RhoB regulation pathway 3.09e-4
Immune response-bacterial infections 7.75e-4
Toll-like receptor signalling pathway leading to proinflammatory response 9.02e-4
EC-MTG TGF, WNT and cytoskeleton remodelling 4.51e-4
Transport Rab-9 regulation pathway 1.48e-3
EC-PCC Immune response-Function MEF2 in T lymphocytes 9.40e-4
Plasmin signalling 3.51e-3
HIP-MTG Transport Rab-3 regulation pathway 6.52e-3
Intracellular cholesterol transport 6.56e-3
HIP-PCC Neurophysiological process - Dopamine D2 receptor transactivation of PDGFR in CNS 9.64e-4
TGF beta mediated regulation of cell proliferation 1.95e-3
PCC-MTG Sorting endosome formation in CF 2.51e-4
Role of inhibitor of apoptosis (IAP) proteins 1.23e-2
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poral gyrus (MTG), superior frontal gyrus (SFG), poster-
ior visual cortex (PVC) and posterior cingulate cortex
(PCC) [1]. Ac-cording to literature study in the report
by Liang et al., the SFG shows metabolic changes rela-
tive to normal ageing and the PVC is spared from age-
related and AD-related neurodegeneration [1].
It is conceivable that if a region is minimally affected
by AD or AD-like (such as ageing) neurodegeneration,
then inflammation or immune response related path-
ways will not be very statistically significant - as we
have already reasoned that they are secondary processes
in AD. When we analysed the DE genes of the SFG and
PVC, we found this to be the case. While there were
immune response pathways, there were many develop-
ment and cytoskeletal related pathways. From these
r e s u l t sw ec o n c l u d et h a tb yu s i n go u rm e t h o dw ec a n
identify that the MTG does not seem to be as severely
affected as the other 3 regions.
As a comparison, we identified the significant path-
ways of all the intersection genes (Number of genes
shown in Table 2, column 2) in the six comparisons.
T a b l e4l i s t ss o m eo ft h et o ps i g n i f i c a n tp a t h w a y so f
these intersection genes. Another comparison was ana-
lysing the differentially expressed genes between regions,
i.e. DE genes that are AD relevant (i.e. comparing AD
affected and controls within a region) as well as those
that have differential expression across two regions. The
top significant pathways, if any, are shown in Table 5. It
could be seen from Tables 4 and 5, that there were a lot
of similarities among the different regions and the dif-
ferences between regions did not stand out as in Table
3. Such analyses and results are ineffectual in making
any deductions about the disease stages in the regions.
We also examined the degree/connectivity of the zero
TO genes in the coexpression networks (see Additional
files 1 and 3). We found several AD associated genes
that showed a marked difference in connectivity
between the region-specific coexpression networks. Cas-
pase-6 (CASP6 ) was present in the list of 180 zero TO
genes between the MTG-PCC, 271 genes between the
HIP-MTG and 192 genes between the EC-MTG. CASP6
has been associated with early AD pathogenesis [51,52].
CASP6 was connected to 3 genes in the MTGnet and
11 in the HIPnet; 3 genes in the MTGnet and 24 in the
PCCnet; and 21 genes in the ECnet and 6 genes in the
MTGnet. Based on the large difference in connectivity
between the region-specific networks, and the high con-
nectivity in certain regions (EC, HIP and PCC) which
we have previously suggested are severely affected, we
hypothesised that CASP6 acts more aggressively in the
later stages of the disease. CASP6 has been implicated
in the early pathogenesis of Alzheimer’s disease and
continues to be an active participant in the later stages
of the disease [52,53]. Furthermore, caspases are the
principal executioners of apoptosis while the inhibitor of
apoptosis proteins (IAP) are caspase inhibitors [54]. The
IAP pathway was enriched in the set of 180 zero TO
genes between the MTGnet and PCCnet. This further
suggests that MTG shows early AD pathology. Beta
Table 4 Significant biological pathways represented in the set of intersection genes between regions
Region comparison Pathways p value (FDR = 0.05)
EC-HIP NF-AT signaling in Cardiac Hypertrophy 6.711e-7
Role of heterochromatin protein 1 (HP1) family in transcriptional silencing 3.309e-6
NGF activation of NF-kB 9.559e-6
EC-MTG Cytoskeleton remodelling Neurofilaments 3.564e-8
Oxidative phosphorylation 1.314e-6
Development-A2B receptor: action via G-protein alpha s 2.328e-5
EC-PCC Role of heterochromatin protein 1 (HP1) family in transcriptional silencing 5.846e-7
Cytoskeleton remodelling-TGF, WNT and cytoskeletal remodelling 7.951e-7
Chemokines and adhesion 5.369e-6
HIP-MTG Oxidative phosphorylation 1.615e-24
Ubiquinone metabolism 2.971e-12
Clathrin-coated vesicle cycle 3.490e-8
HIP-PCC Oxidative phosphorylation 6.858e-13
TGF, WNT and cytoskeletal remodelling 1.037e-7
Role of 14-3-3 proteins in cell cycle regulation 2.839e-7
PCC-MTG Oxidative phosphorylation 1.003e-32
Ubiquinone metabolism 3.485e-16
Clathrin-coated vesicle cycle 1.789e-8
Identification of differentially expressed (DE) genes was carried out by comparing AD affected and unaffected samples within a region. The intersection of the DE
genes between two regions was extracted and significant pathways identified (See Table 2, column 2).
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was present in the set of 271 HIP-MTG zero TO genes.
Increased levels of BACE2 is associated with early AD,
and its expression is negatively correlated with disease
progression [57,58]. It was connected to 24 genes in the
M T G n e t ,c o m p a r e dt o3g e n e si nt h eH I P n e t .BACE2
has been shown to be linked more to amyloid pathology
than to neurofibrillary tangles pathology. This is sup-
ported by the evidence that it has a higher connectivity
in the MTGnet, which is more susceptible to amyloid
deposits than to neurofibrillary tangles [1]. Glutaminase
2( GLS2 ) was connected to 82 genes in the MTGnet
and 17 genes in the PCCnet; 78 genes in the MTG and
3 genes in the HIP. Studies have shown large reductions
in GLS2 activity in the brains of Alzheimer’ss u b j e c t s
[59]. This is also evident from the lower number of con-
nections of GLS2 in the PCC and HIP, a further indica-
tor of PCC and HIP showing signs of late AD
pathology. Brain-specific tubulin polymerisation promot-
ing protein (TPP/p25 ) had 60 neighbours in the
MTGnet and 3 neighbours in the HIPnet. TPPP/p25 is
an inhibitor of glycogen synthase kinase 3, thereby sup-
pressing the phosphorylation of tau [60]. This competi-
tive action fails during the evolution of tau pathology in
the later AD stages. P21 activated kinase 3 (PAK3 )h a d
72 neighbours in the MTGnet and 3 in the HIPnet. Stu-
dies show that PAK3 levels were increased in early AD
subjects, but declined in subjects with severe AD
[61,62]. A few other examples of AD genes with a
higher number of connections in MTGnet and lower
connectivity in the other region-specific networks are
insulin-like growth factor 2 receptor and cadherin 10.
Studies have reported the decrease in expression of
these genes with AD progression. Some genes with a
lower connectivity in the MTGnet and higher connectiv-
ity in the other networks are caspase-3, semaphorin 3A,
inducible nitric oxide synthase and nicastrin. The activ-
ity of these genes have been shown to be decreased in
early AD pathogenesis. These results suggest that large
differences in connectivity probably reflect the difference
in the gene’s activity in the different disease stages.
There were genes whose increased/decreased connec-
tivity did not correlate with the in-creased/decreased
activity in AD. However, in the majority of such cases,
the temporal increase or decrease of a gene’s expression
in the course of the disease was not evaluated in the
published reports. A gene’s expression, although ele-
vated from normal controls, can have a fluctuating
response during disease progression. Such genes warrant
further characterisation and our differential network
method can aid in generating hypotheses related to this.
Further remarks
The gene expression data analysed here was from the
same organ and homogeneous cell population. There-
fore, more similarities than differences are expected
among brain regions with regard to AD affected path-
ways. However, identifying what differences, if any, are
present among the AD affected regions may shed more
light onto the disease progression. In this work, we pre-
sented a novel differential network topology method to
examine four AD affected brain regions for differences
in disease stages. This approach takes advantage of the
logic that due to the progressive nature of the disease,
Table 5 Significant biological pathways in the set of differentially expressed genes between regions
Region comparison (# DE genes) Pathways p value (FDR = 0.05)
EC-HIP (1349) Ossification and bone remodelling 6.395e-3
Cell cycle G2-M 8.544e-3
Cardiac development FGF-ErbB signalling 9.847e-3
Cell cycle-Mitosis 1.159e-2
EC-MTG (567) Development 5.836e-5
Transport-RAB3 regulation pathway 1.695e-4
EC-PCC (1685) Role of 14-3-3 proteins in cell cycle regulation 1.188e-5
Parkin disorder under Parkinson disease 1.474e-5
TGF, WNT and cytoskeletal remodelling 2.738e-5
HIP-MTG (403) Immune response-T cell receptor signalling 1.947e-6
Immune response-Fc epsilon RI pathway 3.021e-6
Dopamine D2 receptor transactivation of PDGFR in CNS 3.335e-6
HIP-PCC (259) Immune response-Function of MEF2 in T lymphocytes 5.157e-8
Immune response-CCR3 signalling in eosinophils 1.593e-6
Immune response-Fc epsilon RI pathway 1.853e-6
PCC-MTG (210) none at FDR = 0.05 -
Identification of differential expression was carried out across two brain regions by directly comparing the expression profiles of the two regions. The biological
pathways of this set of differentially expressed genes between the regions was investigated and shown here.
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therefore, would show different stages of AD progres-
sion/pathogenesis. We believe that such approaches that
can investigate the differences across the affected brain
regions from expression data collected from distinct
brain regions are enabling tools for understanding AD
progression and identifying signs of early pathology.
An alternate method of identifying significant path-
ways specific to a brain region, is to analyse the genes
that are specifically expressed in the brain region, i.e.
remove the genes that are common to two regions and
analyse the genes unique to each region, instead of ana-
lysing the common genes. Our analyses using this
approach didn’ts h o wm a r k e dd i fferences between
regions (data not shown). Furthermore, the same gene
can have different functions depending on the physiolo-
gical condition or brain region. Many genes have been
known to play either destructive or protective roles
depending on the condition, such as DNA repair genes
allowing apoptosis or fighting against apoptosis. Further-
more, many genes also depict changes in their activity
over the course of a disease. Our objective in this study
was to analyse genes whose behaviour changed across
regions, and determine if such changes in behaviour
could characterise the difference in disease severity.
A natural step in this analyses could be the construc-
tion of gene co-expression networks using the union of
the DE genes between two brain regions. In this case,
some genes would be present in the network that were
not considered differentially expressed in a certain
region. Genes not considered significantly DE in any
region could be due to 2 reasons - (a) noisy expression
data and therefore not informative or (b) no change in
expression in that region. We noticed that statistically
significant DE genes with low gene expression tended to
have lower network connectivity in that regional net-
work. Moreover, if a gene has low expression in both
regions or high expression in both regions, it does not
have a large connectivity difference between the two
regional networks. Since we are only analysing genes that
have statistically significant differential expression, we
can interpret downstream results with more confidence
and not expect the results being due to chance. In our
analyses on genes with a large difference in their network
connectivity, we attribute this to their down regulation in
a certain stage of AD because we know that certain
regions get affected later on in the course of AD progres-
sion and therefore show early molecular changes occur-
ring in AD. However, if genes that are not DE in a region
are included in the network, we would not be able to
ascertain whether the connectivity difference was due to
statistically insignificant changes in expression (either
due to technical regions or biological) or because they
were truly up or down regulated in that stage of AD.
There has not been much documentation of AD pro-
gression in the MTG [63], nor any analysis of the MTG
from a systems biology viewpoint. MTG has been
thought to play a role in face recognition, which is
known to be a latter symptom of AD. Our results sug-
gested that the middle temporal gyrus is not as severely
affected as the other three regions. The large physiologi-
cal differences, evidenced by the significant pathways,
and the large difference in gene connectivity between
the MTG and the other three regions were the bases for
this conclusion. Based on this observation we speculate
that post-mortem analyses of the MTG in end-stage AD
affected individuals could shed more light onto early
AD pathogenesis. Our analyses showed that network
topological differences between different brain regions
can aid in identifying pathways that differ between
regions if there is a large difference in the underlying
processes between the regions. Furthermore, the associa-
tion between a gene’s activity and disease severity could
be determined by examining its connectivity across the
networks.
We did not perform this study expecting the method
to show that MTG would be less severely affected. After
all the analyses of the different comparisons were com-
pleted, we were able to search for processes of interest
(such as cytoskeletal, transport, etc.) in the list of DE
genes in the SFG and PVC as well as conclude that
MTG is not severely affected. Nevertheless, by looking
at the DE genes of the 4 AD affected regions one cannot
clearly identify which processes to analyse further or
r e a c hs u c hac o n c l u s i o n .S i n ce our conclusions regard-
ing the MTG conform to what is already known from
imaging and neuropathological reports, speaks well of
the ability of this approach compared to other existing
methods. Our results provide additional insights from a
genetic and genomic perspective, bridging a gap
between genetic information and disease phenotypes,
and complement the findings from imaging and neuro-
pathological studies. Furthermore, a conclusion from
such analyses is a form of independent and unbiased
conclusion. These facts pave the way for applying this
novel method to investigate other lesser understood
human diseases and conditions, as well as time course
analysis, in order to generate testable hypotheses or, the
more interesting scenario of comparing mild cognitive
impairment (MCI) and AD. This paper has presented
the application of this analysis method by applying to a
well studied disease with a good microarray dataset so
that results can be verified via literature search. Experi-
mental validation of 100 s of genes is neither feasible
nor cost effective. Therefore, it would be prudent to
f i r s tt e s tt h em e t h o do nw e l ls t u d i e dt o p i c s .W ea r e
currently applying this method (with good results) to
study time-dependent and dose-dependent response to
Ray and Zhang BMC Systems Biology 2010, 4:136
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Page 9 of 11low-dose ionising radiation in a 3-D skin model (manu-
script under preparation).
We performed our analyses with the differentially
expressed genes between AD affected and normal con-
trols within each region for computational simplicity as
well as to have more confidence in the interpretation of
results as these DE genes are considered AD-perturbed
genes. However, coexpression networks can be built
using all the genes on the microarray chip. In order to
preserve computational simplicity as well as include as
many genes as possible, we used a relaxed FDR of 0.5%
to select DE genes so that a larger number of genes
could be common to the pairs of regions analysed.
Although we proposed a particular measure of differ-
ential network topology, any valid measure of differen-
tial topology can be used. The same rationale applies to
the TO threshold as well. The rationale is that network
differences between data, that are more similar than dif-
ferent, may help in highlighting and understanding the
causes of the differences in the data. From this study, it
is postulated that methods relating to differential coex-
pression network topology should be included in the
toolkit of techniques employed to study complex dis-
eases such as Alzheimer’s.
Additional material
Additional file 1: Number of network links for all regions. This excel
sheet provides the number of network connection for all the genes in
the network in each region.
Additional file 2: Six comparisons and twelve coexpression
networks of the four regions. There were six comparisons among four
brain regions. The coexpression networks for regions were built using
the intersection genes of the regions being compared. The resulting
networks built from the intersection genes are shown on the right.
Additional file 3: Lists of TO genes. This excel sheet lists all the genes
with zero topological overlap between regions.
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